P1.01-001 Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK+ NSCLC in the ALTA TrialD. Ross Camidge, D. Kim, Natasha B. Leighl et al.|Journal of Thoracic Oncology|2017Cited by 3